© 2022 MJH Life Sciences and Oncology Nursing News. All rights reserved.
© 2022 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
March 30, 2022
Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, highlights the importance of relatlimab/nivolumab’s recent FDA approval in melanoma.
January 28, 2022
LAG-3 represents a potentially relevant immune checkpoint pathway in melanoma treatment.
January 19, 2022
Dr. Hussein Tawbi, MD, PhD, explains the rationale behind the RELATIVITY-047 trial in melanoma and how the LAG-3 findings could further revolutionize immunotherapy.